menu
    • menu
    [{"orgOrder":0,"company":"ORIC Pharmaceuticals","sponsor":"Bayer AG","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"ORIC-944","moa":"Polycomb repressive complex-2","graph1":"Oncology","graph2":"Phase I","graph3":"ORIC Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ORIC Pharmaceuticals \/ Bayer AG","highestDevelopmentStatusID":"6","companyTruncated":"ORIC Pharmaceuticals \/ Bayer AG"},{"orgOrder":0,"company":"ORIC Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ORIC-944","moa":"Polycomb repressive complex-2","graph1":"Oncology","graph2":"Phase I","graph3":"ORIC Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ORIC Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ORIC Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ORIC Pharmaceuticals","sponsor":"SR One","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Private Placement","leadProduct":"ORIC-944","moa":"||PRC2","graph1":"Oncology","graph2":"Phase I","graph3":"ORIC Pharmaceuticals","amount2":0.13,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.13,"dosageForm":"Oral","sponsorNew":"ORIC Pharmaceuticals \/ SR One","highestDevelopmentStatusID":"6","companyTruncated":"ORIC Pharmaceuticals \/ SR One"}]

    Find Clinical Drug Pipeline Developments & Deals for ORIC-944

    Menu

    ORIC-944

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            ORIC Pharmaceuticals

                            U.S.A arrow
                            IOPC
                            Not Confirmed

                            ORIC Pharmaceuticals

                            U.S.A arrow
                            IOPC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ORIC-944,Abiraterone Acetate,Apalutamide

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : SR One

                            Deal Size : $125.0 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            ORIC Pharmaceuticals Announces $125 Million Private Placement Financing

                            Details : ORIC intends to use the net proceeds to fund research and development of its clinical-stage product candidates, including ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2.

                            Product Name : ORIC-944

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            May 28, 2025

                            Lead Product(s) : ORIC-944,Abiraterone Acetate,Apalutamide

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : SR One

                            Deal Size : $125.0 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            ORIC Pharmaceuticals

                            U.S.A arrow
                            IOPC
                            Not Confirmed

                            ORIC Pharmaceuticals

                            U.S.A arrow
                            IOPC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ORIC-944

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ORIC Pharmaceuticals Shares Initial Phase 1b Data for ORIC-944 and Upcoming Milestones

                            Details : ORIC-944 is a potent and selective allosteric inhibitor of PRC2. It is under phase 1 clinical development for the treatment of metastatic prostate cancer.

                            Product Name : ORIC-944

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            August 01, 2024

                            Lead Product(s) : ORIC-944

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            ORIC Pharmaceuticals

                            U.S.A arrow
                            IOPC
                            Not Confirmed

                            ORIC Pharmaceuticals

                            U.S.A arrow
                            IOPC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ORIC-944

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Bayer AG

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            ORIC Announces Collaborations to Evaluate ORIC-944 for Prostate Cancer

                            Details : The collaboration with Bayer and J&J will assist in advancing ORIC-944, PRC2 inhibitor, which will be evaluated in combination with darolutamide and apalutamide in patients with mCRPC.

                            Product Name : ORIC-944

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            July 16, 2024

                            Lead Product(s) : ORIC-944

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Bayer AG

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth